A 70-year-old woman with ST-segment elevation myocardial infarction (STEMI) underwent primary percutaneous coronary intervention (pPCI). Before the pPCI, she received dual antiplatelet therapy (a total of six tablets taken as a loading dose without much water) and maintained a supine position for several hours. The patient experienced back pain during the pPCI procedure, and blood testing showed a hemoglobin level of 10.0g/dL. During gastroscopy after the pPCI, a thin white coat of esophageal erosion was noted (Fig. 1a, b). A clopidogrel tablet (red arrow) was seen remaining in the esophagus (Fig. 1c). Gastroscopic image obtained 1 week after pPCI shows healing of the epithelial membrane (Fig. 1d).

The antiplatelet therapy was discontinued, and the patient was treated with an intravenous high calorie diet and proton pump inhibitor for 1 week. A second gastroscopy showed healing of the esophageal epithelial membrane (Fig. 1d) and no evidence of gastric ulcer. No stent thrombosis occurred during the recovery period, and she resumed her daily intake of 100mg of aspirin.

It is not clear if the drug itself caused the widespread exfoliation of the lower esophageal mucosa seen in this patient. Another possibility is that the exfoliation resulted from ischemic mucosal damage or “stress” associated with STEMI, and the drug exacerbated the problem to some extent. Because clopidogrel is a prodrug and exerts its antiplatelet effect after absorption, the clopidogrel tablet itself probably stimulated the esophageal mucosa in the present case [1 – 3]. To avoid such undesirable situations, a patient with STEMI who is undergoing pPCI should take an adequate amount of water with the pills and should maintain a right lateral decubitus position for a few minutes in the emergency room before going to the catheter laboratory.

It is not clear if the drug itself caused the widespread exfoliation of the lower esophageal mucosa seen in this patient. Another possibility is that the exfoliation resulted from ischemic mucosal damage or “stress” associated with STEMI, and the drug exacerbated the problem to some extent. Because clopidogrel is a prodrug and exerts its antiplatelet effect after absorption, the clopidogrel tablet itself probably stimulated the esophageal mucosa in the present case [1 – 3]. To avoid such undesirable situations, a patient with STEMI who is undergoing pPCI should take an adequate amount of water with the pills and should maintain a right lateral decubitus position for a few minutes in the emergency room before going to the catheter laboratory.

Acknowledgement
The authors wish to thank Heidi N. Bonneau, RN, MS, CCA, and Hideaki Kaneda, MD, PhD, for their expert review of this report.

References

Bibliography
DOI http://dx.doi.org/10.1055/s-0034-1393231
Endoscopy 2015; 47: E508
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0013-726X

Corresponding author
Tomomi Koizumi, MD
Division of Cardiovascular Medicine
Saitama International Medical Center
Saitama Medical University
1397-1 Yamane
Hidaka
Saitama 350-1298
Japan
Fax: +81-42-984-4741
tkoizumi@saitama-med.ac.jp